Dissociating the Clinical Role and Economic Value of Intranasal Esketamine

Abstract

Perspectives on ValueApproximately 2 decades ago, the first study to evaluate the use of ketamine for depression was published and disrupted how we think about depression treatment. 1 The study was conducted with intravenous ketamine and has been replicated many times in robust study settings. 2 Although ketamine had been used as an anesthetic since the 1960s, it was not until the 2000s that the psychiatric utility of ketamine gained mainstream attention. 3 The majority of the evidence base for the control in treatment-resistant depression.

Ketamine—50 years in use: from anesthesia to rapid antidepressant effects and neurobiological mechanisms

“…With S-ketamine being approved by the U.S. Food and Drug Administration (FDA) for alleviating symptoms of treatment-resistant depression in 2019, the use of intranasal S-ketamine is likely to increase in the coming years. However, concerns have been expressed over the cost-effectiveness of this intranasal formulation [112].…”

Ketamina eta esketaminaren erabilera depresioerresistentea tratatzeko: etorkizunerako erronkak

“…Tratamenduaren kostu ekonomikoari dagokionez, esketaminaren erabileraren urteko kostu gordinak ketaminarenak baino 10 aldiz handiagoak Ketamina eta esketaminaren erabilera depresio erresistentea tratatzeko: etorkizunerako erronkak dira [61]. Institute for Clinical and Economic Reviewk, kostu-eraginkortasun balantzerako erabiltzen duen neurri estandarraren (quality-adjusted lifeyear) arabera, esketaminak sudur-bideko sendagai baten arrazoizko kostua gainditzen duela adierazi du [62]. Zentzu berean, esketamina depresioaren aurkako beste farmako batzuekin aztertu da, eta emaitzek kostuaren eta eraginkortasunaren arteko balantzea negatiboa dela erakutsi dute.…”